E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Results of a Phase I/II Study of the Combination of 5-aza-2′-Deoxycytidine (DAC) and Valproic Acid (VPA) in Patients (pts) with Leukemia.
Guillermo Garcia-Manero,Hagop M. Kantarjian,Blanca Sanchez-Gonzalez,Stefan Faderl,Srdan Verstovsek,Farhad Ravandi,Michael Ryttling,Jorge E. Cortes,William G. Wierda,Koyu Hoshino,Hui Yang,Claritsa Santos-Malave,Jackie Fiorentino,Elias Jabbour,Gary L. Rosner,Jean Pierre J. Issa +15 more
TL;DR: The combination of low dose DAC and VPA up to doses of 50 mg/kg can be safely administered to pts with leukemia although it may be complicated by neurotoxicity.
Journal ArticleDOI
Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia.
Tapan M. Kadia,Hagop M. Kantarjian,Guillermo Garcia-Manero,Gautam Borthakur,Xuemei Wang,Keyur P. Patel,Elias Jabbour,Mark Brandt,Naval Daver,Naveen Pemmaraju,Sherry Pierce,Jorge E. Cortes,Farhad Ravandi +12 more
TL;DR: Patients with newly diagnosed, non-M3 acute myeloid leukaemia (AML) treated between 1993 and 2012 with available cytogenetic data were analysed based on the European Leukaemia Net (ELN) and UK Medical Research Council classification (MRC-C) systems.
Journal ArticleDOI
An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
Nicholas J. Short,Marina Konopleva,Tapan M. Kadia,Partow Kebriaei,Naval Daver,Xuelin Huang,Lucia Masarova,Robin Cook,Nitin Jain,Elias Jabbour,Hagop M. Kantarjian,Farhad Ravandi +11 more
Journal ArticleDOI
Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia.
Kamal Chamoun,Hagop M. Kantarjian,Xuemei Wang,Kiran Naqvi,Fleur M. Aung,Guillermo Garcia-Manero,Gautam Borthakur,Elias Jabbour,Tapan M. Kadia,Naval Daver,Courtney D. DiNardo,Nitin Jain,Marina Konopleva,Jorge E. Cortes,Farhad Ravandi,Musa Yilmaz +15 more
TL;DR: The objective of the current study was to identify the risk factors associated with transfer to the intensive care unit (ICU) and endotracheal intubation during induction therapy in patients with APL.
Journal ArticleDOI
Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes
Rashmi Kanagal-Shamanna,Guillermo Montalban-Bravo,Koji Sasaki,Faezeh Darbaniyan,Elias Jabbour,Carlos E. Bueso-Ramos,Yue Wei,Kelly S. Chien,Tapan M. Kadia,Farhad Ravandi,Gautam Borthakur,Kelly A. Soltysiak,Mark J. Routbort,Keyur P. Patel,Sherry Pierce,L. Jeffrey Medeiros,Hagop M. Kantarjian,Guillermo Garcia-Manero +17 more
TL;DR: In this article, the authors analyzed the clinicopathological features and outcomes of a single-institution series of 94 treatment-naive SF3B11mut K700E patients (18%) and 415 treatment-nane SF3b11wt MDS patients and explored the differences between K700e and non-K700E SF3-1mut MDS.